Based on these results, another CVOT (IRIS trial) was conducted, that consisted patients with insulin resistance (majority pre-diabetics) and demonstrated a highly significant reduction in primary endpoint (fatal and non-fatal MI or fatal and non-fatal stroke), but there was no difference in terms of total stroke incidences, HHF, and all-cause mortality [ 34 ].
← all excerpts
Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases.
1
—
—